CD20 Antibody (MEM-97) - Azide and BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP1-44634

Clone MEM-97 was used by HLDA to establish CD designation.
Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP1-44634
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Validated:

Human, Porcine, Bovine

Cited:

Bovine

Applications

Validated:

CyTOF-ready, Flow Cytometry, Immunoprecipitation

Cited:

Flow Cytometry

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # MEM-97

Format

Azide and BSA Free

Concentration

1.0 mg/ml

View all CD20 Antibodies »

Product Specifications

Immunogen

Raji human Burkitt's lymphoma cell line (NM_021950.3).

Epitope

extracellular

Specificity

The antibody MEM-97 reacts with CD20 (Bp35), a 33-37 kDa non-glycosylated membrane receptor with four transmembrane domains, expressed on B lymphocytes (it is lost on plasma cells), follicular dendritic cells, and at low levels on peripheral blood T lymphocytes. HLDA V; WS Code B CD20.9

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Theoretical MW

37 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Scientific Data Images for CD20 Antibody (MEM-97) - Azide and BSA Free

Flow Cytometry: CD20 Antibody (MEM-97) - Azide and BSA Free [NBP1-44634]

Flow Cytometry: CD20 Antibody (MEM-97) - Azide and BSA Free [NBP1-44634]

Flow Cytometry: CD20 Antibody (MEM-97) - Azide Free [NBP1-44634] - Double staining of human, canine and porcine B lymphocytes with anti-CD79a (HM57) and anti-CD20 (MEM-97) antibody.
Flow Cytometry: CD20 Antibody (MEM-97) - Azide and BSA Free [NBP1-44634]

Flow Cytometry: CD20 Antibody (MEM-97) - Azide and BSA Free [NBP1-44634]

Flow Cytometry: CD20 Antibody (MEM-97) - Azide Free [NBP1-44634] - A cell surface stain was performed on Raji cells with MS4A1/CD20 antibody (MEM-97) NBP1-44634AF488 (blue) along with a matched isotype control NBP2-27287AF488 (orange). Cells were incubated in an antibody dilution of 10 ug/mL for 20 minutes at room temperature.
Flow Cytometry: CD20 Antibody (MEM-97) - Azide and BSA Free [NBP1-44634]

Flow Cytometry: CD20 Antibody (MEM-97) - Azide and BSA Free [NBP1-44634]

Flow Cytometry: CD20 Antibody (MEM-97) - Azide Free [NBP1-44634] - A cell surface stain was performed on Daudi cells with MS4A1/CD20 (MEM-97) antibody NBP1-44634PE (blue) along with a matched isotype control NBP2-27287PE (orange). Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin.
View 4 more images

Applications for CD20 Antibody (MEM-97) - Azide and BSA Free

Application
Recommended Usage

Flow Cytometry

10 ug/ml

Immunoprecipitation

1:50
Application Notes
This antibody is Cytof ready.

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

PBS (pH 7.4), 0.2 um filter sterilized

Format

Azide and BSA Free

Preservative

No Preservative

Concentration

1.0 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C. Do not freeze.

Background: CD20

CD20 is a non-glycosylated phosphoprotein that is expressed on the surface of normal and malignant B cells and functions in mediating calcium transport and B cell differentiation (1,2). CD20 is encoded by the membrane-spanning 4-domain family A member 1 (MS4A1) gene and, in humans, is located on chromosome 11q12 (1). The CD20 protein is 297 amino acids (aa) in length with a theoretical molecular weight (MW) of 33 kDa (1,2). Structurally, the CD20 protein has four membrane-spanning domains, two extracellular loop domains, and intracellular N- and C-terminal domains (1,2). CD20 is expressed at specific stages of B cell maturation including pre-B cells, mature naive and activated B cells, and memory B cells, but is absent from plasmablasts and plasma cells (1,3,4). Expression of CD20 is often increased on malignant B cells associated with various B cell disorders such as chronic lymphocytic leukemia (CLL), multiple sclerosis (MS), and rheumatoid arthritis (2-4). Anti-CD20 monoclonal antibody (mAb)-based therapies have become an appealing target for treating these immune-related disorders and cancers (1-5). Rituximab, a chimeric mAb, was the first FDA approved CD20 monoclonal antibody for the treatment of non-Hodgkin's lymphoma that is now commonly used to treat MS (2,3). Since its initial approval in 1997, several other chimeric and humanized anti-CD20 mAbs have been developed including Ofatumumab, Ublituximab, and Obinutuzumab (1-5). B cell depletion via CD20 mAbs can occur under different mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis (1-4). Many ongoing studies are focused on combination therapies with CD20 mAbs as an addition to chemotherapy, B cell receptor (BCR) signaling inhibitors, or BH3 mimetics (1,2,4). Additionally, the effects of bispecific antibodies and CD20 chimeric antigen receptor (CAR) T cell therapies are under investigation for the treatment of B cell malignancies (4,5).

References

1. Pavlasova G, Mraz M. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. Haematologica. 2020; 105(6):1494-1506. https://doi.org/10.3324/haematol.2019.243543

2. Payandeh Z, Bahrami AA, Hoseinpoor R, et al. The applications of anti-CD20 antibodies to treat various B cells disorders. Biomed Pharmacother. 2019; 109:2415-2426. https://doi.org/10.1016/j.biopha.2018.11.121

3. Margoni M, Preziosa P, Filippi M, Rocca MA. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol. 2022; 269(3):1316-1334. https://doi.org/10.1007/s00415-021-10744-x

4. Klein C, Jamois C, Nielsen T. Anti-CD20 treatment for B-cell malignancies: current status and future directions. Expert Opin Biol Ther. 2021; 21(2):161-181. https://doi.org/10.1080/14712598.2020.1822318

5. Sharman JP. Targeting CD20: teaching an old dog new tricks. Hematology Am Soc Hematol Educ Program. 2019; 2019(1):273-278. https://doi.org/10.1182/hematology.2019000031

Long Name

Cluster of Differentiation 20

Alternate Names

B1, Bp35, CD20, LEU-16, Ly-44, MS4A1, S7

Entrez Gene IDs

931 (Human); 931 (Human)

Gene Symbol

MS4A1

UniProt

P11836

Additional CD20 Products

Product Documents for CD20 Antibody (MEM-97) - Azide and BSA Free

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for CD20 Antibody (MEM-97) - Azide and BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.